Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade N/A
- Symbol (MURA)
- Company Mural Oncology plc
- Price $3.14
- Changes Percentage (2.95%)
- Change $0.09
- Day Low $3.06
- Day High $3.22
- Year High $6.25
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-207,447,000
Income Statement
Quarterly
Annual
Latest News of MURA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
OpenAI considering restructuring to for-profit, CTO Mira Murati and two top research execs depart
OpenAI's board is discussing restructuring to a for-profit business while keeping the non-profit segment separate. High-level executives, including CTO Mira Murati, are leaving amid the company's grow...
By NBC News | 4 days ago -
OpenAI's technology chief Mira Murati, two other research executives to leave
By Anna Tong(Reuters) -Three top technical leaders at Microsoft-backed OpenAI quit on Wednesday, the latest in a string of executive departures this year coming at a time of flux for the ChatGPT maker...
By Reuters | 4 days ago -
OpenAI's chief research officer has left following CTO Mira Murati's exit
OpenAI's Chief Research Officer Bob McGrew and VP Barret Zoph have resigned, following CTO Mira Murati's departure. CEO Sam Altman announced leadership changes, with Mark Chen as SVP of research, and ...
By Yahoo! Finance | 5 days ago